Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program

VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") with Nanosoft Polymers ("Nanosoft"), a biotechnology-focused polymer company, as an initial step toward negotiating a services agreement related to polymer process development, analytical characterization, and drug formulation optimization activities for the Company's exclusively licensed PNKP Inhibitor Technology, ONC010. The LOI is non-binding, and there is no certainty that a services agreement will be entered into.

Nanosoft specializes in the development of functional polymers and copolymers for drug delivery, diagnostics and therapeutic applications. Nanosoft is led by Dr. Xiaobing Xiong, an experienced polymer scientist with extensive expertise in translational polymer engineering and nanotechnology-enabled drug delivery systems. Dr. Xiong worked under the guidance of Dr. Afsaneh Lavasanifar, a leading nanoparticle scientist at the University of Alberta. Both Dr. Xiong and Dr. Lavasanifar are co-inventors of Onco-Innovations' patented nano delivery system.

The LOI sets out the parties' intent to negotiate toward definitive documentation for proposed polymer-related development activities, which is expected to include polymer synthesis and process optimization, analytical characterization methodology support, formulation optimization activities, encapsulated API development support, and process transfer planning intended to support potential future GMP manufacturing activities.

"This LOI with Nanosoft represents a solid preliminary step as we continue building the technical framework around ONC010. Polymer engineering and nanoparticle formulation are important components of our development pathway, and the proposed relationship with Nanosoft is intended to support further planning around scalability, reproducibility and regulatory readiness," said Thomas O'Shaughnessy, Chief Executive Officer of Onco-Innovations.

Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations, added, "The development of nanoparticle-based oncology therapeutics requires careful integration of polymer science, formulation engineering and analytical characterization. Dr. Xiong's prior experience with the Company's proprietary nano delivery system, together with Nanosoft's polymer-focused expertise, provides a strong basis for the proposed relationship contemplated by the LOI as we continue preparing ONC010 for future clinical and regulatory development activities."

Schreibe Deinen Kommentar